Elsevier Nanoformulation Strategies for Cancer Treatment (Micro and Nano Technologies)

Nanoformulation Strategies for Cancer Treatment provides an up-to-date review on current developments and regulatory and clinical challenges in the field of nanopharmaceuticals and the effective treatment of diverse varieties of cancer. This important reference source is ideal for biomaterials scientists and pharmaceutical scientists working in the area of cancer diagnosis and therapy. Due to the high cost of traditional cancer treatment types, researchers have increasingly looked for new ways to augment the therapeutic performance of existing drug candidates. The use of nanotechnology-based approaches have gained significant momentum, thus leading to the launch of a series of new drug products. As nanopharmaceuticals improve the therapeutic performance of cancer therapy drugs, but also provide opportunities for site-specific drug targeting in tumors, this work is a welcomed resource on the topics discussed. Review Assesses how nanotechnology-based medicines are leading to more efficient and lower cost drug delivery systems for a variety of cancer treatments About the Author Sarwar Beg is Assistant Professor at Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Prior to joining Jamia Hamdard, Dr. Sarwar was worked with Jubilant Generics Limited, Noida, as Research Scientist and was responsible for QbD implementation in formulation and analytical development of generic products. He has over a decade of experience in the field of pharmaceutics, especially in the systematic development and characterization of novel and nanostructured drug delivery systems employing Quality by Design (QbD), Design of Experiments (DoE) and multivariate statistical approaches. Besides, Dr. Sarwar has good knowledge in applying various other advanced computational tools like drug release kinetic modeling, pharmacokinetic modeling and in vitro/in vivo correlation (IVIVC) approaches for efficient development of drug products. Dr. Beg has participated and presented his research work at several conferences in USA, Canada, China, India, Bangladesh, and has earned several “Best Paper awards. Mahfoozur Rahman, PhD, is an Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Allahabad, India. His major areas of research interest include development and characterization of nanosized drug delivery systems for inflammatory disorders including psoriasis, arthritis, neurodegenerative disorders and cancer, etc. Besides, he is also working on amalgamation of herbal medicinal plants with modern therapeutics in order to deliver a scientifically acceptable therapy for various diseases management. To date he has published over 100 publications in peer reviewed journals. Dr. Hani Choudhry is an Associate Professor of Genomics and the Head of Cancer and Mutagenesis Unit at the King Fahd Center for Medical Research in King Abdulaziz University (KAU), Saudi Arabia. Dr. Choudhry completed his DPhil in Clinical Medicine in Prof. Sir Peter Ratcliffe (Nobel Laureate 2019)’s lab at the Wellcome Trust Center for Human Genetics, University of Oxford, UK. Dr. Choudhry has received a number of international and prestigious awards including two AACR Scholar-in-Training Award, the Susan G. Komen for the Cure Award, the ASHG/Charles J. Epstein Trainee Award for Excellence in Human Genetics Research (SF), the Professional Achievement Award and the National Cancer Research Institute (NCRI) Prize Award. He was awarded by the British Embassy and the UAE International Genetic Disorders Prevention Award- Scientific Excellence Award in GCC. Dr. Choudhry’s current scientific interests focus on developing genomic technologies, and the integration of both clinical and pathological information with data generated from high-throughput molecular techniques. His work address